If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a ...

A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and ...

Novo Nordisk A/S (NYSE:NVO) is among the. Novo Nordisk A/S (NYSE:NVO) lowered its operating profit growth projections to ...

On this news, Novo Nordisk's stock price fell $15.06, or 21.8%, to close at $53.94 per share on July 2, 2025, thereby injuring investors. What Is The Lawsuit About?

If you’re pregnant or hoping to become pregnant, it’s natural to have questions about your medications. And if you’re taking ...

A wide variety of unapproved FDA drugs were discovered during inspections, including nearly 55,000 fake injectables and pills ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below ...

For dividend-seeking investors, a buoyant stock market can be a little annoying. Stock prices rising faster than profits ...

Flush with Trump connections, Ballard Partners is D.C.’s new lobbying powerhouse — and its clients are reaping the benefits.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NOVO NORDISK A/S (NVO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Novo between May 7, 2025, to July 28, 2025 and would ...